Studies on the role of basic fibroblast growth factor in vivo

Inability of neutralizing antibodies to block tumor growth

Phillip A. Dennis, Daniel B. Rifkin

Research output: Contribution to journalArticle

Abstract

Affinity-purified polyclonal rabbit antibodies prepared against recombinant basic fibroblast growth factor (bFGF) neutralized the ability of bFGF to stimulate plasminogen activator (PA) production and endothelial cell migration in vitro. After iodination and intraperitoneal injection of the antibodies in mice, approximately 76% of the maximum circulating level of 125I-anti-bFGF antibodies (AF) was found as intact IgG after 24 hr. Furthermore, the circulating 125I-AF retained the ability to bind bFGF. Studies were performed to determine whether the growth of three different murine tumors (CT26, EHS, or B16/BL6) could be inhibited with affinity-purified neutralizing antibodies against bFGF. Tumors were injected subcutaneously in syngeneic mice, and neutralizing antibodies against bFGF were injected daily into the peritoneum. All studies, which varied in tumor burden, antibody dose, and study length, indicated that neutralizing antibodies against bFGF had no effect on tumor size, tumor growth, or tumor histology.

Original languageEnglish (US)
Pages (from-to)84-98
Number of pages15
JournalJournal of Cellular Physiology
Volume144
Issue number1
StatePublished - Jul 1990
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 2
Neutralizing Antibodies
Tumors
Growth
Neoplasms
Antibodies
Experimental Sarcomas
Neoplasm Antibodies
Histology
Plasminogen Activators
Halogenation
Peritoneum
Endothelial cells
Tumor Burden
Intraperitoneal Injections
Cell Movement
Endothelial Cells
Immunoglobulin G
Rabbits

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Studies on the role of basic fibroblast growth factor in vivo : Inability of neutralizing antibodies to block tumor growth. / Dennis, Phillip A.; Rifkin, Daniel B.

In: Journal of Cellular Physiology, Vol. 144, No. 1, 07.1990, p. 84-98.

Research output: Contribution to journalArticle

@article{f1bbde0d595c4379ac84dbd6b3f82f96,
title = "Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growth",
abstract = "Affinity-purified polyclonal rabbit antibodies prepared against recombinant basic fibroblast growth factor (bFGF) neutralized the ability of bFGF to stimulate plasminogen activator (PA) production and endothelial cell migration in vitro. After iodination and intraperitoneal injection of the antibodies in mice, approximately 76{\%} of the maximum circulating level of 125I-anti-bFGF antibodies (AF) was found as intact IgG after 24 hr. Furthermore, the circulating 125I-AF retained the ability to bind bFGF. Studies were performed to determine whether the growth of three different murine tumors (CT26, EHS, or B16/BL6) could be inhibited with affinity-purified neutralizing antibodies against bFGF. Tumors were injected subcutaneously in syngeneic mice, and neutralizing antibodies against bFGF were injected daily into the peritoneum. All studies, which varied in tumor burden, antibody dose, and study length, indicated that neutralizing antibodies against bFGF had no effect on tumor size, tumor growth, or tumor histology.",
author = "Dennis, {Phillip A.} and Rifkin, {Daniel B.}",
year = "1990",
month = "7",
language = "English (US)",
volume = "144",
pages = "84--98",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Studies on the role of basic fibroblast growth factor in vivo

T2 - Inability of neutralizing antibodies to block tumor growth

AU - Dennis, Phillip A.

AU - Rifkin, Daniel B.

PY - 1990/7

Y1 - 1990/7

N2 - Affinity-purified polyclonal rabbit antibodies prepared against recombinant basic fibroblast growth factor (bFGF) neutralized the ability of bFGF to stimulate plasminogen activator (PA) production and endothelial cell migration in vitro. After iodination and intraperitoneal injection of the antibodies in mice, approximately 76% of the maximum circulating level of 125I-anti-bFGF antibodies (AF) was found as intact IgG after 24 hr. Furthermore, the circulating 125I-AF retained the ability to bind bFGF. Studies were performed to determine whether the growth of three different murine tumors (CT26, EHS, or B16/BL6) could be inhibited with affinity-purified neutralizing antibodies against bFGF. Tumors were injected subcutaneously in syngeneic mice, and neutralizing antibodies against bFGF were injected daily into the peritoneum. All studies, which varied in tumor burden, antibody dose, and study length, indicated that neutralizing antibodies against bFGF had no effect on tumor size, tumor growth, or tumor histology.

AB - Affinity-purified polyclonal rabbit antibodies prepared against recombinant basic fibroblast growth factor (bFGF) neutralized the ability of bFGF to stimulate plasminogen activator (PA) production and endothelial cell migration in vitro. After iodination and intraperitoneal injection of the antibodies in mice, approximately 76% of the maximum circulating level of 125I-anti-bFGF antibodies (AF) was found as intact IgG after 24 hr. Furthermore, the circulating 125I-AF retained the ability to bind bFGF. Studies were performed to determine whether the growth of three different murine tumors (CT26, EHS, or B16/BL6) could be inhibited with affinity-purified neutralizing antibodies against bFGF. Tumors were injected subcutaneously in syngeneic mice, and neutralizing antibodies against bFGF were injected daily into the peritoneum. All studies, which varied in tumor burden, antibody dose, and study length, indicated that neutralizing antibodies against bFGF had no effect on tumor size, tumor growth, or tumor histology.

UR - http://www.scopus.com/inward/record.url?scp=0025340141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025340141&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 84

EP - 98

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 1

ER -